Literature DB >> 3409000

Identification and quantification of kynurenic acid in human brain tissue.

W A Turski1, M Nakamura, W P Todd, B K Carpenter, W O Whetsell, R Schwarcz.   

Abstract

Serial ion-exchange and high-performance liquid chromatography separations were employed for the tissue extraction and purification of kynurenic acid (KYNA). Subsequently, the compound isolated from postmortem human brain tissue was unequivocally identified as KYNA by nuclear magnetic resonance and mass spectrometric analyses. Regional distribution analyses revealed the highest concentration of KYNA (1.58 +/- 0.43 pmol/mg tissue) in the caudate nucleus with lower levels in the thalamus, globus pallidus, hippocampus, parietal cortex and frontal cortex. Of the brain structures examined, the lowest concentration of KYNA (0.14 +/- 0.02 pmol/mg tissue) was found in the cerebellum.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3409000     DOI： 10.1016/0006-8993(88)90815-3

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  54 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

2.  Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro.

Authors:  Claudia Di Serio; Andrea Cozzi; Ilaria Angeli; Laura Doria; Isabella Micucci; Silvia Pellerito; Patrizia Mirone; Giulio Masotti; Flavio Moroni; Francesca Tarantini
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

3.  Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

Authors:  K Rejdak; A Petzold; T Kocki; J Kurzepa; P Grieb; W A Turski; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

4.  Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure.

Authors:  Juntuo Zhou; Xi Chen; Wei Chen; Lijun Zhong; Ming Cui
Journal:  Mol Cell Biochem       Date:  2021-05-11       Impact factor: 3.396

5.  Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor.

Authors:  Hui-Qiu Wu; Masahiro Okuyama; Yasushi Kajii; Ana Pocivavsek; John P Bruno; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

Review 6.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

7.  Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain.

Authors:  M Grilli; L Raiteri; L Patti; M Parodi; F Robino; M Raiteri; M Marchi
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

8.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

9.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.